Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Y5 antisense ODN used to confirm involvement of this receptor in the regulation of feeding

Dec. 23, 1998

Another novel class of nonsteroidal progesterone receptor agonists designed by Ligand

Dec. 23, 1998

Somatostatin agonists from Takeda claimed for diabetes and its complications

Dec. 23, 1998

Structure revealed by Tanabe Seiyaku for potent, orally active SGLT inhibitor

Dec. 22, 1998

AxyS and Merck extend osteoporosis collaboration

Dec. 22, 1998

Kinetek initiates phase I studies of type II diabetes treatment

Dec. 22, 1998

Preliminary analysis of phase II trial indicates efficacy and safety of Topiglan gel

Dec. 21, 1998

E.U.-wide Muse approval triggers license and milestone payments from Astra

Dec. 21, 1998

Collaborative effort at SB and NPS results in development of small-molecule calcilytic

Dec. 18, 1998

New market release for sildenafil

Dec. 18, 1998

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....